6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy
In-Person Event
Sep 11 - 12, 2026
San Francisco, California, USA
10 MOC ...
53 Day(s) leftOVERVIEW
6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy is organized by Binaytara Foundation (BTF) and will be held from Sep 11 - 12, 2026 at Hyatt Regency San Francisco Downtown Soma, San Francisco, California, United States of America.
Description:
The 6th National Precision Oncology Summit is a CME-accredited two-day conference convening leading experts in cancer genomics, molecular diagnostics, targeted therapy, and next-generation oncology modalities. Held in San Francisco, this annual summit has established itself as one of the foremost national meetings dedicated to bridging the science of precision medicine with everyday oncology practice.
The 2026 program addresses the full precision oncology continuum germline cancer predisposition and biomarker-driven therapy selection, to cutting-edge topics in antibody-drug conjugates, radioligand therapies, targeted protein degraders, RAS and small-molecule inhibitors, and off-the- shelf CAR-T and cell therapies. Dedicated molecular tumor board sessions challenge attendees with complex real-world cases, while a focused session on artificial intelligence explores how machine learning is reshaping oncology diagnostics and clinical decision-making. The summit also spotlights Binaytara's work in reducing cancer care disparities and features oral abstract presentations from emerging investigators.
Learning Objectives:
At the conclusion of this activity, participants should be able to:
- Distinguish germline from somatic alterations in cancer predisposition and apply this understanding to biomarker-driven therapy selection, including current targeted agents and near-pipeline drugs.
- Evaluate advances in molecular diagnostics including ctDNA-based MRD detection, multi-cancer early detection, and treatment-emergent resistance mutations and their implications for clinical decision-making.
- Analyze the mechanisms of action, clinical data, and appropriate use of antibody-drug conjugates, radioligand therapies, targeted protein degraders, and key small-molecule inhibitors across relevant tumor types.
- Identify mechanisms of drug resistance in precision oncology adaptive bypass pathways, epigenetic alterations, microenvironment contributions - and apply evidence-based strategies to address them.
- Integrate artificial intelligence, machine learning, and molecular tumor board frameworks into oncology clinical workflows to enhance diagnostic accuracy and support individualized treatment planning.
KEY DATES
10 Jul, 2026
Registrations Open
11 Sep, 2026
Event Start Date
12 Sep, 2026
Event End Date
ACCREDITATION & CREDITS
10.00 AMA PRA Category 1 Credit™
The Binaytara is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara designates this live activity for a maximum of 10.00 6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
10.00 ABIM MOC II
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
10.00 ACPE Pharmacy
The Binaytara is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to the activity is Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the 6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy activity will not be awarded the CEUs. The Binaytara may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®. After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.
10.00 Nursing Contact Hours
Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.00 Contact Hours.
TARGET AUDIENCE
PhysicianOncologistsHematologistMedical GeneticistsPathologistsFellowsMedical OncologistsAdvanced Practice ProvidersLaboratory Medicine SpecialistsSPECIALITIES
OncologySUGGESTED HOTELS
CONFERENCE VENUE
Hyatt Regency San Francisco Downtown Soma
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
RELATED CONFERENCES & LIVE WEBINARS
Quick Links